152 related articles for article (PubMed ID: 37651468)
1. Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell Lymphoma.
Álvarez-Benedicto E; Tian Z; Chatterjee S; Orlando D; Kim M; Guerrero ED; Wang X; Siegwart DJ
Angew Chem Int Ed Engl; 2023 Oct; 62(44):e202310395. PubMed ID: 37651468
[TBL] [Abstract][Full Text] [Related]
2. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
[TBL] [Abstract][Full Text] [Related]
3. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
4. In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism.
Billingsley MM; Gong N; Mukalel AJ; Thatte AS; El-Mayta R; Patel SK; Metzloff AE; Swingle KL; Han X; Xue L; Hamilton AG; Safford HC; Alameh MG; Papp TE; Parhiz H; Weissman D; Mitchell MJ
Small; 2024 Mar; 20(11):e2304378. PubMed ID: 38072809
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo.
Zhou JE; Sun L; Jia Y; Wang Z; Luo T; Tan J; Fang X; Zhu H; Wang J; Yu L; Yan Z
J Control Release; 2022 Oct; 350():298-307. PubMed ID: 36002054
[TBL] [Abstract][Full Text] [Related]
7. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
Ren CX; Chen XX; Zhao L; Tian Y; Xu KL; Zhao K
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):506-512. PubMed ID: 35968595
[No Abstract] [Full Text] [Related]
8. In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.
Ye Z; Chen J; Zhao X; Li Y; Harmon J; Huang C; Chen J; Xu Q
ACS Biomater Sci Eng; 2022 Feb; 8(2):722-733. PubMed ID: 35104103
[TBL] [Abstract][Full Text] [Related]
9. CAR T cells produced in vivo to treat cardiac injury.
Rurik JG; Tombácz I; Yadegari A; Méndez Fernández PO; Shewale SV; Li L; Kimura T; Soliman OY; Papp TE; Tam YK; Mui BL; Albelda SM; Puré E; June CH; Aghajanian H; Weissman D; Parhiz H; Epstein JA
Science; 2022 Jan; 375(6576):91-96. PubMed ID: 34990237
[TBL] [Abstract][Full Text] [Related]
10. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.
Tombácz I; Laczkó D; Shahnawaz H; Muramatsu H; Natesan A; Yadegari A; Papp TE; Alameh MG; Shuvaev V; Mui BL; Tam YK; Muzykantov V; Pardi N; Weissman D; Parhiz H
Mol Ther; 2021 Nov; 29(11):3293-3304. PubMed ID: 34091054
[TBL] [Abstract][Full Text] [Related]
11. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
[TBL] [Abstract][Full Text] [Related]
12. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
13. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift.
Kheirolomoom A; Kare AJ; Ingham ES; Paulmurugan R; Robinson ER; Baikoghli M; Inayathullah M; Seo JW; Wang J; Fite BZ; Wu B; Tumbale SK; Raie MN; Cheng RH; Nichols L; Borowsky AD; Ferrara KW
Biomaterials; 2022 Feb; 281():121339. PubMed ID: 35078042
[TBL] [Abstract][Full Text] [Related]
14. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
15. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.
Ye B; Hu Y; Zhang M; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):185-191. PubMed ID: 36161298
[TBL] [Abstract][Full Text] [Related]
16. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
17. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
20. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]